Global Website
Home
Leadership Transition at Physidia: Julien Dolivet Named New President
Physidia, Europe’s leading player in home hemodialysis, announces today a significant management transition with the appointment of Julien Dolivet as President, following Didier Candelot.
Didier Candelot, who joined Physidia in October 2019, played a pivotal role in establishing the company as a leader in innovative home hemodialysis development, production, and commercialization. He will continue supporting the company’s growth as part of its strategic advisory board.
“Leading Physidia over the past four years has been a privilege. I am proud of what we have achieved together as a team to strengthen Physidia’s leadership position in Europe, enhance our operational excellence, and significantly improve the company’s financial profile. Physidia is now ready to embark on a new phase of accelerated growth, led by my successor, Julien Dolivet, who will leverage the resources of our new partner, Columna Capital,” said Didier Candelot.
Julien Dolivet joins Physidia with a wealth of experience in the home care industry. His professional journey spans roles such as Global VP of Marketing at Hollister Inc., CEO of French home care company FSK, and Managing Director France & Benelux at Linde Healthcare. Combining his home care expertise with a clear vision for the renal sector, Julien Dolivet is exceptionally equipped to lead Physidia in advancing its mission of improving patients’ lives through innovative home hemodialysis solutions.
“Joining Physidia at such a defining moment for the company and the sector is a privilege. As the transition to home-based care accelerates worldwide, Physidia is fundamentally redefining home hemodialysis, backed by 10 years of market presence and exceptional results. I aim to leverage my experience in home care to drive our mission, extend our footprint, and keep delivering patient-centered, high-quality home dialysis solutions,” said Julien Dolivet.
This transition in leadership marks a new chapter in Physidia’s journey, as the company continues to play a pivotal role in advancing the home hemodialysis market, with particular attention to improving patient quality of life. The move follows a significant investment from Columna Capital, designed to accelerate international growth and ensure ongoing support for R&D initiatives.
